$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
Pitobrutinib/Pitobrutinib (Zepali) drug basic information and main parameter description
2026-02-01 22:25:32
Check Details
Price reference and purchase method of Talazoparib in the Canadian market
2026-02-01 22:25:32
Check Details
Analysis of whether crizotinib (Xalkori) is the last hope for patients and its clinical choice
2026-02-01 22:25:32
Check Details
Remedies for missed doses of aprocitentan and tips to avoid blood pressure fluctuations
2026-02-01 22:25:32
Check Details
Recommendations for the use of tilpotide/tirsiparatide (Mufenda) in special populations
2026-02-01 22:25:32
Check Details
Pitobrutinib/Pitobrutinib (Zepali) generally requires several courses of treatment to be effective
2026-02-01 22:25:32
Check Details
The best daily taking time and medication precautions for Talazoparib (Tazena)
2026-02-01 22:25:32
Check Details
Analysis of treatment methods and protocols after emergence of resistance to crizotinib (Xalkori)
2026-02-01 22:25:32
Check Details
Guanfacine extended-release tablets (Guanfacine) common side effects, safety monitoring and long-term medication risk analysis
2026-02-01 22:25:32
Check Details
Pacritinib (pacritinib) India price, formal import channels and clinical use reference analysis
2026-02-01 22:25:32
Check Details
Analysis of the scope of indications and clinical application of Letermovir (Premin)
2026-02-01 22:25:32
Check Details
Etrasimod tablets (Etrasimod)-Velsipity clinical efficacy performance, patient feedback and use experience analysis
2026-02-01 22:25:32
Check Details
1
2
...
2382
2383
2384
2385
2386
2387
2388
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
User Agreement
2
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
3
What is the most important information I should know about WELIREG?
4
How to take and store WELIREG
5
How to take TRUSELTIQ correctly
6
How to deal with LONSURF side effects (1)
7
How to deal with LONSURF side effects (2)
8
Cabozantinib (Cabometyx)-new indication approved
9
What should I pay attention to when using atezolizumab/Tecentriq?
10
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma
11
Rituximab combined with chemotherapy approved in the United States for pediatric patients with specific malignant tumors
12
Lenvatinib and pembrolizumab trial results in unresectable hepatocellular carcinoma